CINIE CINIE
中文 | English | Français | Русский
Home CINIE World Nuclear Fusion Nuclear Application

Search Results

Keyword:radionuclide drug conjugate

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

Reading Ranking

  • 1 New York State Power Authority Selects 10 Nuclear Power Developers
  • 2 Hungarian Government Advances Comprehensive Audit of Paks II Nuclear Power Project
  • 3 French and US Companies Join Forces to Supply Advanced Lead-Cooled Fast Reactor Recycled Fuel
  • 4 Ontario Power Generation Adjusts SMR Project Schedule
  • 5 CNNC 24th Construction Refreshes Construction Progress at Nuclear Power and Key Projects in Multiple Locations
  • 6 Turkey's Akkuyu Nuclear Power Plant Plans to Start Nuclear Fuel Loading Next Month
  • 7 US Nuclear Regulatory Commission Delays Review Milestone for Orano Enrichment Plant
  • 8 The Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment Holds Briefing on New Standard
  • 9 Swedish and UK Companies Sign Advanced Nuclear Fuel Supply Agreement
  • 10 UK Nuclear Workforce Grows by Over 7%
  • 11 Aktis Oncology Expands Clinical Enrollment for Actinium-Based Radiopharmaceuticals
  • 12 Texas A&M University Conducts Electron Beam Pest Sterilization Trials
  • 13 Containment Test of the First Unit at Akkuyu Nuclear Power Plant in Türkiye
  • 14 MEPhI Achieves Breakthrough in Composite Material Fabrication for Fusion Reactor Walls
  • 15 South Korea Adds 1 Trillion Won in Fusion Investment: From 48-Second High-Temperature Plasma to an Industrial System Capable of Building Reactors
CINIE

Organizing Committee of the Shenzhen Nuclear Expo

Telephone: +86 10-67808008

+86 10-68808008

Email: info@cinie.net

CINIE

Event Overview Support Services Highlights Archive Contact Us

World Nuclear

China Nuclear Power News World Nuclear Power News Expert Views Nuclear Power Technology

Fusion

China Fusion World Fusion Big Science Facilities ITER Program Business & Capital

Nuclear Application

Medical Scientific Research Environmental Protection Industry Food Agriculture Security
About us | All rights reserved
CINIE All rights reserved 2026 ICP License:京ICP备12027382号-9